-
A one-size-fits-all education about heart disease is not a good strategy, according to Holly Andersen, MD, director of education and outreach at the Ronald O. Perelman Heart Center at New York-Presbyterian Hospital Weill Cornell Medical Center in New York City.
-
-
Although some aspects of vaginal birth after cesarean delivery (VBAC) have been covered in previous OB/GYN Clinical Alert issues, I cannot pass up an opportunity to comment on two papers appearing in the June issue of Obstetrics & Gynecology.
-
Carcinosarcoma of the uterus is a rare condition accounting for less that 4% of all uterine neoplasms. Previous work has identified that the most active single agents are platinum, ifosfamide, paclitaxel, and doxorubicin.
-
Without fanfare, the FDA approved oral tranexamic acid tablets (Lysteda), the first non-hormonal product cleared to treat heavy menstrual bleeding in the United States.
-
In this issue: Lorcaserin submitted for FDA review, FDA advisory panel votes against phentermine/topiramate, mixed vote on rosiglitazone, advisory panel votes to remove breast cancer indication from bevacizumab labeling, no increase in seizures found with DTaP vaccine, new REMS for quinine.
-
-
I love this article. It's relevant to our daily practice, but, more importantly, it verbalizes the same issues that both physicians and patients want clarified.
-
-
Add Natazia, an estradiol valerate/dienogest pill, to the list of oral contraceptives approved by the Food and Drug Administration (FDA) and now available to U.S. women.
